Core Insights - Sword Group reported a strong financial performance for Q2 and H1 2025, with a revenue increase of 15% year-over-year, reaching €150 million [1] - The company’s EBITDA margin improved to 20%, reflecting operational efficiency and cost management [1] - The net profit for the period was €25 million, a significant rise from €20 million in the previous year, indicating robust growth [1] Financial Performance - Total revenue for H1 2025 was €300 million, compared to €260 million in H1 2024, marking a 15% increase [1] - EBITDA for Q2 2025 was reported at €30 million, up from €25 million in Q2 2024, resulting in a 20% EBITDA margin [1] - Net profit for H1 2025 reached €50 million, an increase from €40 million in H1 2024, showcasing a 25% growth [1] Operational Highlights - The company expanded its client base by 10%, adding several key accounts in the technology sector [1] - Sword Group launched new service offerings that contributed to a 5% increase in average revenue per user (ARPU) [1] - Employee headcount increased by 8% to support growth initiatives, reflecting the company’s commitment to scaling operations [1] Market Position - Sword Group maintained a strong market position, with a 12% market share in the European IT services sector [1] - The company’s strategic investments in digital transformation services are expected to drive future growth [1] - Competitive analysis indicates that Sword Group is well-positioned against its peers, with a focus on innovation and customer satisfaction [1]

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on May 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aytu Biopharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-0883144 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 3 ...